These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22451619)

  • 1. Abiraterone in prostate cancer: a new angle to an old problem.
    Stein MN; Goodin S; Dipaola RS
    Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M; Garcia JA
    Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
    Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
    Pal SK; Twardowski P; Josephson DY
    Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing therapeutic paradigms in castrate-resistant prostate cancer.
    Zivi A; Massard C; De-Bono J
    Clin Genitourin Cancer; 2010 Dec; 8(1):17-22. PubMed ID: 21208851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
    J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 9. Abiraterone and increased survival in metastatic prostate cancer.
    de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
    N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
    J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
    J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
    J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD; Taplin ME
    Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
    Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
    Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.
    Sartor O
    Nat Rev Clin Oncol; 2011 Aug; 8(9):515-6. PubMed ID: 21808270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
    Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
    Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.